A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 1, 2010, Pages 151-158

  Ramaswamy, Bhuvaneswari ^a   Bekaii Saab, Tanios ^a   Schaaf, Larry J ^a   Lesinski, Gregory B ^a   Lucas, David M ^a   Young, Donn C ^a   Ruppert, Amy S ^a   Byrd, John C ^a   Culler, Kristy ^a   Wilkins, Diedre ^a   Wright, John J ^a   Grever, Michael R ^a   Shapiro, Charles L ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Bortezomib; Paclitaxel; Phase I; Solid tumors

Indexed keywords

BORTEZOMIB; PACLITAXEL; PROTEASOME; PROTEIN BAX; PROTEIN P27; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; CYCLINE; CYTOKINE; P27 ANTIGEN; PYRAZINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD ANALYSIS; BRAIN ISCHEMIA; CANCER GROWTH; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIARRHEA; DOSE CALCULATION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ENZYME INHIBITION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEMOGLOBINOPATHY; HUMAN; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PANCREAS CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SOLID TUMOR; SWEAT GLAND CARCINOMA; THROMBOCYTE DISORDER; THROMBOSIS; VOMITING; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; DRUG ANTAGONISM; METASTASIS; MIDDLE AGED; NEOPLASM; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BCL-2-ASSOCIATED X PROTEIN; BORONIC ACIDS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; NEUTROPENIA; PACLITAXEL; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; TREATMENT OUTCOME;

EID: 77951913630     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1145-z     Document Type: Article

References (37)

1. Adams J (2003) The proteasome: structure, function, and role in the cell. Cancer Treat Rev 29 (Suppl 1):3-9
2. Ciechanover A, Schwartz AL (1998) The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death [comment]. Proc Natl Acad Sci USA 95:2727-2730
3. Adams J (2002) Development of the proteasome inhibitor PS-341. Oncologist 7:9-16
4. Cusack JC (2003) Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treat Rev 29 (Suppl 1):21-31
5. Nencioni A, Grunebach F, Patrone F et al (2007) Proteasome inhibitors: antitumor effects and beyond. Leukemia 21:30-36
6. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T (1994) The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 78:773-785
7. Ling YH, Liebes L, Ng B et al (2002) PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol Cancer Ther 1:841-849
8. Richardson PG, Sonneveld P, Schuster MW (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma [see comment]. N Engl J Med 352:2487-2498
9. Jagannath S, Barlogie B, Berenson J et al (2004) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127:165-172
10. Richardson PG, Barlogie B, Berenson J (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma [see comment]. N Engl J Med 348:2609-2617
11. Millennium Pharmaceuticals I. Velcade Full Prescribing Information. June 2008
12. Papandreou CN, Daliani DD, Nix D et al (2004) Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22:2108-2121
13. Orlowski RZ, Kuhn DJ (2008) Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 14:1649-1657
14. Milano A, Iaffaioli RV, Caponigro F (2007) The proteasome: a worthwhile target for the treatment of solid tumours? Eur J Cancer 43:1125-1133
15. Mitsiades CS, McMillin D, Kotoula V et al (2006) Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J Clin Endocrinol Metab 91:4013-4021
16. Orlowski RZ, Eswara JR, Lafond-Walker A et al (1998) Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 58:4342-4348
17. Teicher BA, Ara G, Herbst R et al (1999) The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 5:2638-2645
18. Orlowski RZ (1999) The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Differ 6:303-313
19. Cresta SSC, Catapano CV, Gallerani E, Passalacqua D, Rinaldi A, Bertoni F, Vigano L, maur M, Capri G, Maccioni E, Tosi D, Gianni L (2008) Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumors. Eur J Cancer. doi: 10.1016/j.ejca.2008.05.022
20. Ma C, Mandrekar SJ, Alberts SR et al (2007) A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies. Cancer Chemother Pharmacol 59:207-215
21. Canfield SE, Zhu K, Williams SA, McConkey DJ (2006) Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells. Mol Cancer Ther 5:2043-2050
22. Adams J (2002) Proteasome inhibitors as new anticancer drugs. Curr Opin Oncol 14:628-634
23. Gehan EA, Tefft MC (2000) Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors) ? [comment]. J Natl Cancer Inst 92:179-181
24. Lightcap ES, McCormack TA, Pien CS et al (2000) Proteasome inhibition measurements: clinical application. Clin Chem 46:673-683
25. Aron JL, Parthun MR, Marcucci G et al (2003) Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood 102:652-658
26. Yang CH, Gonzalez-Angulo AM, Reuben JM et al (2006) Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann Oncol 17:813-817
27. Aghajanian C, Soignet S, Dizon DS et al (2002) A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8:2505-2511
28. Awada A, Albanell J, Canney PA et al (2008) Bortezomib/docetaxel combination therapy in patients with anthracyclinepretreated advanced/metastatic breast cancer: a phase I/II doseescalation study. Br J Cancer 98:1500-1507
29. Cohen SJ, Engstrom PF, Lewis NL et al (2008) Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors. Am J Clin Oncol 31:1-5
30. Dreicer R, Petrylak D, Agus D et al (2007) Phase I/II study of bortezomib plus docetaxel in patients with advanced androgenindependent prostate cancer. Clin Cancer Res 13:1208-1215
31. Pinkus H, Mehregan AH (1963) Epidermotropic eccrine carcinoma: a case combining features of eccrine poroma and Paget's dermatosis. Arch Dermatol 88:597-606
32. Snow SN, Reizner GT (1992) Mucinous eccrine carcinoma of the eyelid. Cancer 70:2099-2104
33. Robson A, Greene J, Ansari N (2001) Eccrine porocarcinoma (malignant eccrine poroma) : a clinicopathologic study of 69 cases [see comment]. Am J Surg Pathol 25:710-720
34. Gutermuth J, Audring H, Voit C et al (2004) Antitumour activity of paclitaxel and interferon-alpha in a case of metastatic eccrine porocarcinoma. J Eur Acad Dermatol Venereol 18:477-479
35. Holcomb B, Yip-Schneider M, Schmidt CM (2008) The role of nuclear factor kappaB in pancreatic cancer and the clinical applications of targeted therapy. Pancreas 36:225-235
36. Ashamalla H, Zaki B, Mokhtar B et al. (2003) Hyperfractionated radiotherapy and paclitaxel for locally advanced/unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 55:679-687
37. [erratum appears in Int J Radiat Oncol Biol Phys. Mar. 15;55(4):1158]